SalemLab (@vickysalem_lab) 's Twitter Profile
SalemLab

@vickysalem_lab

clinical diabetologist, islet biologist, bioengineering for type 1 diabetes at Imperial College London - opinions are our own

ID: 1787368793506746368

calendar_today06-05-2024 06:28:36

6 Tweet

46 Followers

59 Following

Diabetes UK Research (@duk_research) 's Twitter Profile Photo

@stevemorganfdn Simon Heller James Cantley Lab Next we’re hearing from Dr Vicky Salem and Rea Tresa who are bio-printing a protective skeleton made of hydrogels, so transplanted beta cells can survive, thrive, and not be broken down by the immune system 💧

@stevemorganfdn <a href="/simonrheller/">Simon Heller</a> <a href="/JamesCantleyLab/">James Cantley Lab</a> Next we’re hearing from Dr Vicky Salem and <a href="/rea_tresa/">Rea Tresa</a> who are bio-printing a protective skeleton made of hydrogels, so transplanted beta cells can survive, thrive, and not be broken down by the immune system 💧
Daniel J Drucker (@danieljdrucker) 's Twitter Profile Photo

New from Prof Salem and colleagues. New roles for intraislet glucagon, calcium signaling and GSIS #islets #insulin sciencedirect.com/science/articl… Imperial College London Diabetes UK Guy Rutter1 #islets #diabetes

New from Prof Salem and colleagues. New roles for intraislet glucagon, calcium signaling and GSIS  #islets #insulin sciencedirect.com/science/articl… <a href="/imperialcollege/">Imperial College London</a> <a href="/DiabetesUK/">Diabetes UK</a> <a href="/guy_rutter/">Guy Rutter1</a> #islets #diabetes
Daniel J Drucker (@danieljdrucker) 's Twitter Profile Photo

GLP-1 medicines started with #T2D then #obesity #heartdisease and now #kidney disease, with semaglutide the evidence leader. As the scope of indications expands, each new entity will be challenged to accumulate robust evidence in multiple indications diabetesjournals.org/care/article/d…

GLP-1 medicines started with #T2D then #obesity #heartdisease and now #kidney disease, with semaglutide the evidence leader. As the scope of indications expands, each new entity will be challenged to accumulate robust evidence in multiple indications diabetesjournals.org/care/article/d…